New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT03156114

First seen Feb 01, 2026 · Last updated May 13, 2026 · Updated 7 times

Summary

This study tested two experimental drugs, BI 754111 and BI 754091, that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and the second part checked if the combination could shrink tumors. Treatment was given every 3 weeks for up to one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BioVirtus Research Site Sp. z o.o.

    Józefów, 05-410, Poland

  • Cross Cancer Institute (University of Alberta)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Florida Cancer Specialists

    Sarasota, Florida, 34232, United States

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28007, Spain

  • Hospital Politècnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitari Dexeus

    Barcelona, 08028, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, 28050, Spain

  • John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Oncology Center-Maria Sklodowska-Curie Institute

    Warsaw, 02-781, Poland

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 1Z9, Canada

  • Sarah Cannon Research Institute

    London, W1G 6AD, United Kingdom

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Tennessee Oncology, PLLC

    Nashville, Tennessee, 37203, United States

  • University of Miami

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.